Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.64+0.02 (+1.23%)
Close on Nov 17, 2026Market cap $11.80MP/E 1.1Yield –
Chemomab Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Chemomab Therapeutics's pe ratio was 0.9× on Nov 11, 2026, against 0.8× a year earlier. Over the last 5 years it ranged from 0.3× to 12.8×, with a median of 1.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.9× | +0.4 |
| 2025 | Dec 31, 2025 | 0.5× | −0.3 |
| 2024 | Dec 31, 2024 | 0.9× | +0.5 |
| 2023 | Dec 29, 2023 | 0.4× | −2.1 |
| 2022 | Dec 30, 2022 | 2.5× | −10.3 |
| 2021 | Dec 31, 2021 | 12.8× | +9.5 |
| 2020 | Jan 31, 2020 | 3.3× | −0.3 |
| 2019 | Dec 31, 2019 | 3.6× | – |
See a number that looks wrong?